{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:44:23Z","timestamp":1790279063197,"version":"4.1.0"},"reference-count":46,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>Rosacea is a chronic, progressive, inflammatory condition phenotypically subtyped into diagnostic features, major features, and minor\/secondary features. There is currently no cure for rosacea, and it carries a significant negative psychosocial burden for afflicted patients. While there are a number of treatment modalities at the disposal of the clinician, clinical experience has suggested a need for updated treatments. The pathogenesis of rosacea is multifactorial; however, this paper will focus on the pivotal role of interleukin 17 (IL-17) in the development and progression of the disease. Furthermore, this paper will explore the mechanism of action of standard rosacea treatments and their effect on different stages of the IL-17 pathway. The standard treatments for rosacea are usually effective in controlling the symptoms of the disease in its mild-to-moderate form; however, their efficacy is diminished in the setting of severe and treatment-resistant rosacea. We hypothesize that IL-17 inhibitors, currently used successfully in psoriasis and psoriatic arthritis, could perhaps be used to treat severe and treatment-resistant papulopustular rosacea in the future; however, clinical trials and case reports will be needed to dictate expanded indications of IL-17 inhibitors. Furthermore, the high cost of IL-17 inhibitors presently prevents their use in disease states other than psoriasis or psoriatic arthritis.<\/jats:p>","DOI":"10.1177\/1203475419867611","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T05:33:58Z","timestamp":1565588038000},"page":"635-641","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":47,"title":["The Role of IL-17 in Papulopustular Rosacea and Future Directions"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1579-6086","authenticated-orcid":false,"given":"Asma","family":"Amir Ali","sequence":"first","affiliation":[{"name":"Schulich School of Medicine & Dentistry, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Vender","sequence":"additional","affiliation":[{"name":"School of Medicine, Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ronald","family":"Vender","sequence":"additional","affiliation":[{"name":"Dermatrials Research Inc., Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"bibr1-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11037.x"},{"key":"bibr2-1203475419867611","first-page":"282","volume":"179","author":"Gether L","year":"2018","journal-title":"Br J Dermatol"},{"key":"bibr3-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03240.x"},{"key":"bibr4-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1461"},{"key":"bibr5-1203475419867611","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091562"},{"key":"bibr6-1203475419867611","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2335"},{"key":"bibr7-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.141"},{"key":"bibr8-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00700.x"},{"key":"bibr9-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.07.018"},{"key":"bibr10-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.526"},{"key":"bibr11-1203475419867611","first-page":"26","volume":"2","author":"Jones DA.","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"bibr12-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2011.9"},{"key":"bibr13-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70065-2"},{"key":"bibr14-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12030"},{"key":"bibr15-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020014"},{"key":"bibr16-1203475419867611","first-page":"385352","author":"Zheng Y","year":"2014","journal-title":"J Immunol Res"},{"key":"bibr17-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-9295"},{"key":"bibr18-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.05.019"},{"key":"bibr19-1203475419867611","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.10608"},{"key":"bibr20-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.351"},{"key":"bibr21-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1038\/nm1616"},{"key":"bibr22-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08196.x"},{"key":"bibr23-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12745"},{"key":"bibr24-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2011.6"},{"key":"bibr25-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2011.4"},{"key":"bibr26-1203475419867611","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.12.8504"},{"key":"bibr27-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-016-1892-y"},{"key":"bibr28-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2017.07.005"},{"key":"bibr29-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2010.08.009"},{"key":"bibr30-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850193"},{"key":"bibr31-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1007\/BF00402621"},{"key":"bibr32-1203475419867611","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2018.004"},{"key":"bibr33-1203475419867611","first-page":"316","volume":"13","author":"Stein L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"bibr34-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14437"},{"key":"bibr35-1203475419867611","first-page":"348","volume":"6","author":"Huynh TT.","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"bibr36-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0249-y"},{"key":"bibr37-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.111"},{"key":"bibr38-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.025"},{"key":"bibr39-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12770"},{"key":"bibr40-1203475419867611","first-page":"198","volume":"14","author":"Wang K","year":"2015","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"bibr41-1203475419867611","doi-asserted-by":"publisher","DOI":"10.1159\/000489092"},{"key":"bibr42-1203475419867611","first-page":"CD003262","volume":"4","author":"van Zuuren EJ","year":"2015","journal-title":"Cochrane Database of Syst Rev"},{"key":"bibr43-1203475419867611","unstructured":"Chang A. Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03079531."},{"key":"bibr44-1203475419867611","unstructured":"Inc. NPC. PRODUCT MONOGRAPH PrCOSENTYX\u00ae (Secukinumab) 2018."},{"key":"bibr45-1203475419867611","unstructured":"Inc. ELC. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrTALTZ\u2122 ixekizumab. 2017."},{"key":"bibr46-1203475419867611","unstructured":"LP VC. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrSILIQ\u2122 brodalumab. 2018."}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475419867611","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1203475419867611","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475419867611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:54:19Z","timestamp":1777391659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1203475419867611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1177\/1203475419867611"],"URL":"https:\/\/doi.org\/10.1177\/1203475419867611","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]}}}